Higher activation levels of effector NK cells in CML patients treated with TKI might reflect minimization of BCR-ABL1 transcript levels and therefore could serve as additive information when determining imatinib discontinuation. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.